This site uses cookies to simplify and improve your online experience.  You can find out more about cookies and how you can disable them by reading our Terms and Conditions. By continuing to browse this site you agree to our use of cookies on this device.

Roche Navigation Menu Roche Resources : Roche Resources
  • Sign in
  • Logout
  • Search
Roche
  • Up
  • Home
  • Search
  • Close search

						
							

Searching

    • Home
    • Roche Medicines
      Roche Medicines Overview
      • Oncology
      • ALECENSA®▼(alectinib)
      • Kadcyla® (trastuzumab emtansine)
      • PERJETA® (pertuzumab)
      • PHESGO®▼ (pertuzumab/trastuzumab)
      • TECENTRIQ®▼ (atezolizumab)
      • Rozlytrek▼(entrectinib)
      • Neuroscience
      • OCREVUS®▼ (ocrelizumab)
      • Haematology
      • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
      • Evrysdi®▼ (risdiplam)
      • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      Therapy Areas Overview
      • Oncology
      • Breast Cancer
      • Haematology
      • Haematology
      • Neuroscience
      • Neuroscience
    • Congress and Meetings
      Congress and Meetings Overview
    • HCP Materials
      HCP Materials Overview
    • FAQs
      FAQs Overview
    • Prescribing Information
      Prescribing Information Overview
      • Find out more about:
      • ALECENSA®▼(alectinib)
      • Avastin® (bevacizumab) [Great Britain]
      • Avastin (bevacizumab) [Northern Ireland]
      • Evrysdi®▼(risdiplam)
      • GAZYVARO® (obinutuzumab) Great Britain
      • GAZYVARO® (obinutuzumab) Northern Ireland
      • HEMLIBRA®▼(emicizumab) Great Britain
      • HEMLIBRA®▼(emicizumab) Northern Ireland
      • Herceptin® (trastuzumab) IV
      • Herceptin® (trastuzumab) SC
      • Kadcyla® (trastuzumab emtansine)
      • OCREVUS®▼ (ocrelizumab) GB
      • OCREVUS®▼ (ocrelizumab) NI
      • Perjeta® (pertuzumab)
      • Phesgo®▼(pertuzumab/trastuzumab)
      • Polivy®▼(polatuzumab vedotin)
      • Rozlytrek® ▼(entrectinib)
      • TECENTRIQ®▼ (atezolizumab) Great Britain
      • Tecentriq®▼ (atezolizumab) Northern Ireland
    • Adverse Event Reporting
      Adverse Event Reporting Overview
    • Home
    • Roche Medicines
      • Oncology
        • ALECENSA®▼(alectinib)
        • Kadcyla® (trastuzumab emtansine)
        • PERJETA® (pertuzumab)
        • PHESGO®▼ (pertuzumab/trastuzumab)
        • TECENTRIQ®▼ (atezolizumab)
        • Rozlytrek▼(entrectinib)
      • Neuroscience
        • OCREVUS®▼ (ocrelizumab)
      • Haematology
        • POLIVY®▼ (polatuzumab vedotin)
      • Rare Diseases
        • Evrysdi®▼ (risdiplam)
        • HEMLIBRA®▼ (emicizumab)
    • Therapy Areas
      • Oncology
        • Breast Cancer
      • Haematology
        • Haematology
      • Neuroscience
        • Neuroscience
    • Congress and Meetings
    • HCP Materials
    • FAQs
    • Prescribing Information
      • Find out more about:
        • ALECENSA®▼(alectinib)
        • Avastin® (bevacizumab) [Great Britain]
        • Avastin (bevacizumab) [Northern Ireland]
        • Evrysdi®▼(risdiplam)
        • GAZYVARO® (obinutuzumab) Great Britain
        • GAZYVARO® (obinutuzumab) Northern Ireland
        • HEMLIBRA®▼(emicizumab) Great Britain
        • HEMLIBRA®▼(emicizumab) Northern Ireland
        • Herceptin® (trastuzumab) IV
        • Herceptin® (trastuzumab) SC
        • Kadcyla® (trastuzumab emtansine)
        • OCREVUS®▼ (ocrelizumab) GB
        • OCREVUS®▼ (ocrelizumab) NI
        • Perjeta® (pertuzumab)
        • Phesgo®▼(pertuzumab/trastuzumab)
        • Polivy®▼(polatuzumab vedotin)
        • Rozlytrek® ▼(entrectinib)
        • TECENTRIQ®▼ (atezolizumab) Great Britain
        • Tecentriq®▼ (atezolizumab) Northern Ireland
    • Adverse Event Reporting
    • Sign in
    • Logout
    Close

    1 - of results for ""

    No results

    This website is intended for healthcare professionals (HCPs) only. If you are an HCP, register free to access the full content.


    You are here:

    1. Resources
    2. Congresses and Meetings
    3. 2021 US Oncology Meeting

    #ASCO2021 - Annual US Oncology Meeting
    Breast Cancer Highlights

    The 2021 American Society of Clinical Oncology (ASCO) Annual Meeting took place virtually on 4th–8th June 2021. Key breast cancer data from a UK perspective were identified by a Steering Committee of experts reflecting a range of specialties in breast oncology:

    • Dr Andreas Makris, Consultant Clinical Oncologist (Mount Vernon Cancer Centre, Middlesex) – Steering Committee Chair
    • Dr Caroline Wilson, Consultant Medical Oncologist (Weston Park Hospital, Sheffield)
    • Dr David Miles, Consultant Medical Oncologist (Mount Vernon Cancer Centre, Middlesex)
    • Dr Duncan Wheatley, Consultant Clinical Oncologist (Royal Cornwall Hospital, Truro)
    • Dr Judy King, Consultant Medical Oncologist (Royal Free Hospital, London)
    • Dr Mark Harries, Consultant Medical Oncologist (Guy’s and St Thomas’ Hospital, London)
    • Dr MB Mukesh, Consultant Clinical Oncologist (Colchester General Hospital, Colchester)
    • Mr Mark Sibbering, Consultant Breast Surgeon (University Hospitals of Derby and Burton, Derby)
    • Mr Stuart McIntosh, Consultant Breast Surgeon (Belfast City Hospital, Belfast)
    • Dr Susan Cleator, Consultant Clinical Oncologist (Imperial Hospital Trust, London)

    The Steering Committee viewed the online content, and fed back on the data they believed were most relevant to share with the UK breast oncology clinical community. Key insights from our Steering Committee are presented in the Breast Cancer Highlights Report (click here to download the report).

    All data included in the report fall within the relevant licensed indications for Roche products. Information in the report includes non-Roche medicines that are not licensed in the UK, or being used outside of their licensed indications. Should you require further information on a molecule that is not produced by Roche Products Ltd., please contact the relevant manufacturer. 

     
    Abbreviations:
    ASCO, American Society of Clinical Oncology

     

     

    M-GB-00004808
    Date of preparation: September 2021
     

    Downloads
     

    ASCO 2021 report
    Access the Congress Highlights Report

    This report is intended to be viewed online in your web browser.

    Should you require additional information on breast cancer data presented at the meeting, please click here to contact us.

    Sign in or register

    To learn more about Roche products or meetings and congresses, please sign in or click here to register.

    Access information, news and resources about our medicines and the therapy areas in which they are used.

     

    Welcome to Roche Resources

    Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

    I am a healthcare professional I am a member of the public
    • © 2022 Roche Products Limited
    • 04.04.2022
    • Terms and Conditions
    • Privacy Policy
    • Prescribing Information
    • Contact

    Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. ▼Additional monitoring: Medicinal products associated with this symbol are subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. For biological medicines, healthcare professionals should report adverse reactions by brand name and batch number. This is a promotional website intended for HCPs, designed, built and funded by Roche Products Ltd. Commentary and other materials, including external links, posted on this site are not intended to amount to advice on which reliance should be placed. We therefore disclaim all liability and responsibility arising from any reliance placed on such materials by any visitor to our site, or by anyone who may be informed of any of its contents. M-GB-00006977 Date of Preparation April 2022.